AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04916366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional bandage
Description: It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
Study NCT05634733 — intervention group
Intervention type: OTHER
Intervention: Treatment of Sepsis
Description: Patients will have standard care of sepsis
Study NCT05354895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial infrared laser stimulation
Description: non-invasive, non-pharmacologic photobiomodulation device
Study NCT06138470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron extract
Description: Food supplements are taken during 6 weeks by healthy volunteers
Study NCT06138470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Scutellaria baicalensis extract
Description: Food supplements are taken during 6 weeks by healthy volunteers
Study NCT06138470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron and Scutellaria baicalensis extract
Description: Food supplements are taken during 6 weeks by healthy volunteers
Study NCT06138470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: Food supplements are taken during 6 weeks by healthy volunteers
Study NCT05995496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting state
Description: 16 hours of fasting
Study NCT05995496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting state
Description: 16 hours of fasting
Study NCT05995496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed state
Description: Fed a standardized meal
Study NCT05995496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fed state
Description: Fed a standardized meal
Study NCT05995496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Neuroimaging with computational modeling
Study NCT05995496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Neuroimaging with computational modeling
Study NCT06517277 — intervention group
Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
Study NCT06417476 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose
Study NCT06417476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Study NCT06417476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Study NCT06417476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Formate
Description: 400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Study NCT05450601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2106-1
Description: Take once daily for 2 weeks orally
Study NCT05450601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2103-1
Description: Placebo drug. Take once daily for 2 weeks orally
Study NCT05705778 — intervention group
Intervention type: PROCEDURE
Intervention: standard amblyopia treatment
Description: amblyopia treatment following international guidelines and genetic tests.
Study NCT06365853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Study NCT06365853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubricating Eye Drops
Description: Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.
Study NCT06365853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate ophthalmic suspension 1% eye drops
Description: Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
Study NCT06365853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution eye drops
Description: Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
Study NCT04967248 — intervention group
Intervention type: OTHER
Intervention: Alpelisib
Description: Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
Study NCT04967248 — intervention group
Intervention type: OTHER
Intervention: Fulvestrant
Description: Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
Study NCT05077605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional residual capacity measure by electrical impedance tomography
Description: Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
Study NCT05438407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leniolisib
Description: The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
Study NCT05525013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin Powder
Description: Simvastatin gel placed as an intracanal medication
Study NCT05525013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Calcium hydroxide intracanal medication
Study NCT05836584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT06417476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
Study NCT05836584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05836584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT05450601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2106-2
Description: Take once daily for 6 weeks orally
Study NCT05450601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2103-2
Description: Placebo drug. Take once daily for 6 weeks orally
Study NCT05836584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT05005845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX-179 gel
Description: NFX-179 topical gel is the active investigational product being studied
Study NCT05005845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: NFX-179 vehicle gel is the placebo comparator for this study
Study NCT05836584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT05836584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06417476 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation
Description: The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose
Study NCT06417476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
Study NCT04856085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection
Study NCT05836584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT05836584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT05836584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy
Study NCT05836584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05836584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT05836584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05836584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT06455449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (blinded)
Description: Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
Study NCT06455449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo delivered subcutaneously, once weekly for 52 weeks
Study NCT06455449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (unblinded, open label)
Description: At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
Study NCT06423495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity laser treatment
Description: The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
Study NCT05475210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE
Description: Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
Study NCT05475210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Solution
Description: The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
Study NCT03852992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Laser Minoxidil 2%
Description: 2ml of 20mg/ml sterile solution, applied post-laser procedure
Study NCT03852992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: At-Home Minoxidil 5%
Description: 2ml of 50mg/ml foam q24 h for duration of study
Study NCT03852992 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser
Description: Fractional ablative, deep mode, 5% fractional coverage
Study NCT03852992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Fractional ablative, deep mode, 5% fractional coverage
Study NCT03852992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-laser 5mg minoxidil
Description: 0.25ml of 20mg/ml sterile solution, applied post-laser procedure
Study NCT03852992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-laser 10mg minoxidil
Description: 0.5ml of 20mg/ml sterile solution, applied post-laser procedure
Study NCT03852992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-laser 20mg minoxidil
Description: 1ml of 20mg/ml sterile solution, applied post-laser procedure
Study NCT06267924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband Experimental
Description: Participants will be randomly assigned to use the Otoband Experimental device to determine effectiveness in providing temporary relief to symptoms of vertigo.
Study NCT06267924 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Otoband Sham
Description: Participants will be randomly assigned to use the Otoband Sham device to determine effectiveness in providing temporary relief to symptoms of vertigo.
Study NCT06462235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: ATM-AVI Single Dose, Cohorts 1-4
Description: Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
Study NCT06462235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Multiple-dose ATM-AVI, Cohorts 1-4
Description: Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
Study NCT06337318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06337318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT scan
Study NCT06337318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given SC
Study NCT06337318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT06337318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT06337318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study NCT06649019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism (AO1DfA)
Description: Test Lens
Study NCT06649019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1 for Astigmatism (DT1fA)
Description: Control Lens
Study NCT06400472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4170156
Description: Intravenous
Study NCT05928117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Pregnant women will be given training to cope with the fear of childbirth.
Study NCT05552261 — intervention group
Intervention type: DRUG
Intervention: Cenegemin in the DEFENDO Study
Description: Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial.
Study NCT03184935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
Study NCT03184935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Decitabine
Description: Decitabine，20mg/m\^2/d
Study NCT03184935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine，20mg/m\^2/d
Study NCT05943392 — intervention group
Intervention type: OTHER
Intervention: EEG recording
Description: EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli
Study NCT05943392 — intervention group
Intervention type: OTHER
Intervention: Psychophysics (behavioural experiments)
Description: Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
Study NCT04850196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
Study NCT04850196 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
Study NCT05642195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide (Registered Trademark) ISA-51 VG Adjuvant
Description: H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
Study NCT05642195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1299 Cell Lysates
Description: H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
Study NCT05642195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.
Study NCT05642195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventana PD-L1 (SP263 or SP142) assay
Description: FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.
Study NCT04899999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial reward graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
Study NCT04899999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health reward graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
Study NCT04899999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
Study NCT04899999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norms graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
Study NCT05364970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VR_Training_1PP
Description: Immersive VR scenario of physical training with avatar embodiment
Study NCT05364970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VR_Training_3PP
Description: Immersive VR scenario of physical training without avatar embodiment
Study NCT06499740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted SAFETY-A for PC
Description: This intervention is a suicide prevention intervention that will be adapted from the evidence-based SAFETY-Acute program. The specific intervention components will be determined from information gathered in this study but the investigators anticipate will include components such as safety planning, lethal means restriction, psychoeducation, motivation building, and care linkage.
Study NCT06499740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual delivered in participating clinics.